Obstacles to the Adoption of Biosimilars for Chronic Diseases
There is optimism that biosimilars will offer lower-cost therapeutic alternatives to branded biologic drugs, in the same manner as generic drugs have done for small-molecule drugs. On average, the cost of a small-molecule drug declines by 70% in the 24 months following initial generic approval. Furt...
Gespeichert in:
| Veröffentlicht in: | JAMA : the journal of the American Medical Association 2017-06, Vol.317 (21), p.2163-2164 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2164 |
|---|---|
| container_issue | 21 |
| container_start_page | 2163 |
| container_title | JAMA : the journal of the American Medical Association |
| container_volume | 317 |
| creator | Hakim, Aaron Ross, Joseph S |
| description | There is optimism that biosimilars will offer lower-cost therapeutic alternatives to branded biologic drugs, in the same manner as generic drugs have done for small-molecule drugs. On average, the cost of a small-molecule drug declines by 70% in the 24 months following initial generic approval. Furthermore, generic drugs currently account for 88% of all US prescriptions, yielding 10-year cost savings in excess of $1.5 trillion. Here, Hakim and Ross explore why biosimilars for chronic diseases, the largest category of biological therapies, are unlikely to yield widely expected cost savings. |
| doi_str_mv | 10.1001/jama.2017.5202 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1894519353</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>2625049</ama_id><sourcerecordid>1915869836</sourcerecordid><originalsourceid>FETCH-LOGICAL-a408t-c7be0a48421ee14a1564a8402dbe13a2da0875f57933c8320a18ab990568734e3</originalsourceid><addsrcrecordid>eNpdkD1PwzAQhi0EoqWwMjAgSywsCT5_JPbAUMqnVKkLzJaTOKqrpC52MvDvSdTSgVtuuOd9dXoQugaSAiHwsDGtSSmBPBWU0BM0BcFkwoSSp2hKiJJJziWfoIsYN2QYYPk5mlDJhVKUT9HjqoidKRsbcedxt7Z4Xvld5_wW-xo_OR9d6xoTIq59wIt18FtX4mcXrYk2XqKz2jTRXh32DH29vnwu3pPl6u1jMV8mhhPZJWVeWGKGPyhYC9yAyLiRnNCqsMAMrQyRuahFrhgrJaPEgDSFUkRkMmfcshm63_fugv_ubex062Jpm8Zsre-jBqm4AMUEG9C7f-jG92E7fKdBgZCZkiwbqHRPlcHHGGytd8G1JvxoIHoUq0exehSrR7FD4PZQ2xetrY74n8kBuNkDY-54zaggXLFfJ595sg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1915869836</pqid></control><display><type>article</type><title>Obstacles to the Adoption of Biosimilars for Chronic Diseases</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Hakim, Aaron ; Ross, Joseph S</creator><creatorcontrib>Hakim, Aaron ; Ross, Joseph S</creatorcontrib><description>There is optimism that biosimilars will offer lower-cost therapeutic alternatives to branded biologic drugs, in the same manner as generic drugs have done for small-molecule drugs. On average, the cost of a small-molecule drug declines by 70% in the 24 months following initial generic approval. Furthermore, generic drugs currently account for 88% of all US prescriptions, yielding 10-year cost savings in excess of $1.5 trillion. Here, Hakim and Ross explore why biosimilars for chronic diseases, the largest category of biological therapies, are unlikely to yield widely expected cost savings.</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.2017.5202</identifier><identifier>PMID: 28459924</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Biological products ; Biosimilar Pharmaceuticals - economics ; Biosimilar Pharmaceuticals - therapeutic use ; Chronic Disease - drug therapy ; Chronic illnesses ; Cost engineering ; Cost reduction ; Diffusion of Innovation ; Drug Approval ; Drug Costs ; Drug Industry ; Drug therapy ; Drugs ; Generic drugs ; Humans ; Insurance, Pharmaceutical Services ; Legislation, Drug ; Pharmacies ; State Government ; United States</subject><ispartof>JAMA : the journal of the American Medical Association, 2017-06, Vol.317 (21), p.2163-2164</ispartof><rights>Copyright American Medical Association Jun 6, 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a408t-c7be0a48421ee14a1564a8402dbe13a2da0875f57933c8320a18ab990568734e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jama/articlepdf/10.1001/jama.2017.5202$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2017.5202$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,776,780,3327,27901,27902,76458,76461</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28459924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hakim, Aaron</creatorcontrib><creatorcontrib>Ross, Joseph S</creatorcontrib><title>Obstacles to the Adoption of Biosimilars for Chronic Diseases</title><title>JAMA : the journal of the American Medical Association</title><addtitle>JAMA</addtitle><description>There is optimism that biosimilars will offer lower-cost therapeutic alternatives to branded biologic drugs, in the same manner as generic drugs have done for small-molecule drugs. On average, the cost of a small-molecule drug declines by 70% in the 24 months following initial generic approval. Furthermore, generic drugs currently account for 88% of all US prescriptions, yielding 10-year cost savings in excess of $1.5 trillion. Here, Hakim and Ross explore why biosimilars for chronic diseases, the largest category of biological therapies, are unlikely to yield widely expected cost savings.</description><subject>Biological products</subject><subject>Biosimilar Pharmaceuticals - economics</subject><subject>Biosimilar Pharmaceuticals - therapeutic use</subject><subject>Chronic Disease - drug therapy</subject><subject>Chronic illnesses</subject><subject>Cost engineering</subject><subject>Cost reduction</subject><subject>Diffusion of Innovation</subject><subject>Drug Approval</subject><subject>Drug Costs</subject><subject>Drug Industry</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Generic drugs</subject><subject>Humans</subject><subject>Insurance, Pharmaceutical Services</subject><subject>Legislation, Drug</subject><subject>Pharmacies</subject><subject>State Government</subject><subject>United States</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkD1PwzAQhi0EoqWwMjAgSywsCT5_JPbAUMqnVKkLzJaTOKqrpC52MvDvSdTSgVtuuOd9dXoQugaSAiHwsDGtSSmBPBWU0BM0BcFkwoSSp2hKiJJJziWfoIsYN2QYYPk5mlDJhVKUT9HjqoidKRsbcedxt7Z4Xvld5_wW-xo_OR9d6xoTIq59wIt18FtX4mcXrYk2XqKz2jTRXh32DH29vnwu3pPl6u1jMV8mhhPZJWVeWGKGPyhYC9yAyLiRnNCqsMAMrQyRuahFrhgrJaPEgDSFUkRkMmfcshm63_fugv_ubex062Jpm8Zsre-jBqm4AMUEG9C7f-jG92E7fKdBgZCZkiwbqHRPlcHHGGytd8G1JvxoIHoUq0exehSrR7FD4PZQ2xetrY74n8kBuNkDY-54zaggXLFfJ595sg</recordid><startdate>20170606</startdate><enddate>20170606</enddate><creator>Hakim, Aaron</creator><creator>Ross, Joseph S</creator><general>American Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20170606</creationdate><title>Obstacles to the Adoption of Biosimilars for Chronic Diseases</title><author>Hakim, Aaron ; Ross, Joseph S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a408t-c7be0a48421ee14a1564a8402dbe13a2da0875f57933c8320a18ab990568734e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Biological products</topic><topic>Biosimilar Pharmaceuticals - economics</topic><topic>Biosimilar Pharmaceuticals - therapeutic use</topic><topic>Chronic Disease - drug therapy</topic><topic>Chronic illnesses</topic><topic>Cost engineering</topic><topic>Cost reduction</topic><topic>Diffusion of Innovation</topic><topic>Drug Approval</topic><topic>Drug Costs</topic><topic>Drug Industry</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Generic drugs</topic><topic>Humans</topic><topic>Insurance, Pharmaceutical Services</topic><topic>Legislation, Drug</topic><topic>Pharmacies</topic><topic>State Government</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hakim, Aaron</creatorcontrib><creatorcontrib>Ross, Joseph S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hakim, Aaron</au><au>Ross, Joseph S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Obstacles to the Adoption of Biosimilars for Chronic Diseases</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><addtitle>JAMA</addtitle><date>2017-06-06</date><risdate>2017</risdate><volume>317</volume><issue>21</issue><spage>2163</spage><epage>2164</epage><pages>2163-2164</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><abstract>There is optimism that biosimilars will offer lower-cost therapeutic alternatives to branded biologic drugs, in the same manner as generic drugs have done for small-molecule drugs. On average, the cost of a small-molecule drug declines by 70% in the 24 months following initial generic approval. Furthermore, generic drugs currently account for 88% of all US prescriptions, yielding 10-year cost savings in excess of $1.5 trillion. Here, Hakim and Ross explore why biosimilars for chronic diseases, the largest category of biological therapies, are unlikely to yield widely expected cost savings.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>28459924</pmid><doi>10.1001/jama.2017.5202</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0098-7484 |
| ispartof | JAMA : the journal of the American Medical Association, 2017-06, Vol.317 (21), p.2163-2164 |
| issn | 0098-7484 1538-3598 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1894519353 |
| source | MEDLINE; American Medical Association Journals |
| subjects | Biological products Biosimilar Pharmaceuticals - economics Biosimilar Pharmaceuticals - therapeutic use Chronic Disease - drug therapy Chronic illnesses Cost engineering Cost reduction Diffusion of Innovation Drug Approval Drug Costs Drug Industry Drug therapy Drugs Generic drugs Humans Insurance, Pharmaceutical Services Legislation, Drug Pharmacies State Government United States |
| title | Obstacles to the Adoption of Biosimilars for Chronic Diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T03%3A49%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Obstacles%20to%20the%20Adoption%20of%20Biosimilars%20for%20Chronic%20Diseases&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Hakim,%20Aaron&rft.date=2017-06-06&rft.volume=317&rft.issue=21&rft.spage=2163&rft.epage=2164&rft.pages=2163-2164&rft.issn=0098-7484&rft.eissn=1538-3598&rft_id=info:doi/10.1001/jama.2017.5202&rft_dat=%3Cproquest_cross%3E1915869836%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1915869836&rft_id=info:pmid/28459924&rft_ama_id=2625049&rfr_iscdi=true |